soul trial oral semaglutide cardiovascular outcomes 2024 results nejm reduced the risk of clinically important kidney and death from (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 Oral semaglutide found to lower

Weight Loss Via Lifestyle Intervention Can Change Cardiac Biomarkers A secondary analysis of the LookAHEAD trial showed that lifestyle interventions targeting weight loss for type 2 diabetes patients led to a change in biomarkers associated with higher risk of cardiovascular disease and heart failure (HF)

The ratio matters enormously for long-term success

Clinical evidence for probiotics in weight management remains limited and inconclusive, with modest effects typically not meeting standards for regulatory health claims approval

The terms on the Ozempic Savings Card state that only patients with private or commercial drug insurance policies that cover Ozempic can redeem the coupon and, if eligible, pay as little as $25 for up to a three-month supply